While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Learn how GSK is harnessing the power of technology to improve outcomes for people with cancer.

(Reuters) - European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo ...

Stock prices in London were mixed on Wednesday afternoon, with a share price rise for GSK supporting the FTSE 100, though tariff worries continue to hang over equities. The FTSE 100 index rose 12.01 ...

Science and Technology Secretary Peter Kyle said ... “But through our world-leading universities and businesses working in ...